Crossject
Crossject is a specialty pharmaceutical company focused on drug-device combination products for emergency medicine. Leveraging a proprietary needle-free auto-injection platform, the company develops and manufactures fast-acting treatments for life-threatening situations such as epilepsy, adrenal crisis, and anaphylaxis. Crossject conducts advanced regulatory development, clinical validation, and large-scale industrialization to deliver innovative therapies for global markets, with an emphasis on simplicity, reliability, and patient usability.
Industries
N/A
Crossject
6 rue Pauline Kergomard, 21000 Dijon, France
Patents
Device for monitoring the pressure or alternatively an injection force of a plurality of jets generated at the outlet of a needleless injection device
2025-04-22 • US-12280245-B2
View DetailsOptimised method for filling a pyrotechnic charge and system implementing such a method
2024-07-23 • US-12043423-B2
View DetailsNeedleless injection device equipped with an improved injection nozzle
2024-05-28 • US-11992660-B2
View DetailsMethod for air quenching an elongated glass hollow body comprising an axial bore
2024-03-26 • US-11939254-B2
View Details
Device for monitoring the pressure or alternatively an injection force of a plurality of jets generated at the outlet of a needleless injection device
2025-04-22 • US-12280245-B2
View DetailsOptimised method for filling a pyrotechnic charge and system implementing such a method
2024-07-23 • US-12043423-B2
View DetailsNeedleless injection device equipped with an improved injection nozzle
2024-05-28 • US-11992660-B2
View DetailsMethod for air quenching an elongated glass hollow body comprising an axial bore
2024-03-26 • US-11939254-B2
View DetailsProducts
A proprietary single-use device enabling rapid, reliable delivery of emergency medications without the use of a needle.
A portfolio of drug-device combination candidates targeting life-threatening conditions such as epilepsy (midazolam), adrenal crisis (hydrocortisone), and anaphylaxis (epinephrine).
A proprietary single-use device enabling rapid, reliable delivery of emergency medications without the use of a needle.
A portfolio of drug-device combination candidates targeting life-threatening conditions such as epilepsy (midazolam), adrenal crisis (hydrocortisone), and anaphylaxis (epinephrine).
Expertise Areas
- Emergency drug delivery
- Drug-device combination product development
- Human factors engineering in medical devices
- Clinical evaluation of injectable therapies
Key Technologies
- Needle-free jet injection
- Pre-filled single-use injectors
- Pharmaceutical-grade siliconized glass tube
- Polycarbonate micro-nozzle engineering
Key People
News & Updates
Awarded Silver Level ESG rating for 2023 by EthiFinance.
Received special jury award at '4th Chemistry Meeting' organized by France Chimie Auvergne-Rhône-Alpes in April 2022.
Awarded for fair business practices as part of regional RSE (CSR) Trophies.
Recognized for promotion of sustainable mobility, traveling over 4,500 km with sustainable means in September 2024.
Crossject secures public funding from the French Government for needle-free technology platform.
Crossject presented at the H.C. Wainwright Annual Global Investment Conference.
Awarded Silver Level ESG rating for 2023 by EthiFinance.
Received special jury award at '4th Chemistry Meeting' organized by France Chimie Auvergne-Rhône-Alpes in April 2022.
Awarded for fair business practices as part of regional RSE (CSR) Trophies.
Recognized for promotion of sustainable mobility, traveling over 4,500 km with sustainable means in September 2024.
Crossject secures public funding from the French Government for needle-free technology platform.
Crossject presented at the H.C. Wainwright Annual Global Investment Conference.